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Available online 5 March 2008Carnitine palmitoyltransferase (CPT) I is regulated by several genetic and non-genetic factors including
allosteric inhibition, mitochondrial membrane composition and/or ﬂuidity and transcriptional regulation of
enzyme content. To determine the intrinsic differences in these regulating factors that may result in
differences between tissues in fatty acid oxidation ability, mitochondria were isolated from red, white and
heart muscles and liver tissue from rainbow trout. Maximal activity (Vmax) for β-oxidation enzymes and
citrate synthase per mg tissue protein as well as CPT I in isolated mitochondria followed a pattern across
tissues of red muscleNheartNwhite muscleN liver suggesting both quantitative and qualitative differences in
mitochondria. CPT I inhibition showed a similar patternwith the highest malonyl-CoA concentration to inhibit
activity by 50% (IC50) found in red muscle while liver had the lowest. Tissue malonyl-CoA content was highest
in white muscle with no differences between the other tissues. Interestingly, the gene expression proﬁles did
not follow the same pattern as the tissue enzyme activity. CPT I mRNA expression was greatest in heartN red
muscleNwhite muscleN liver. In contrast, PPARα mRNA was greatest in the liverNred muscleNheartNwhite
muscle. There were no signiﬁcant differences in the mRNA expression of PPARβ between tissues. As well, no
signiﬁcant differences were found in the mitochondrial membrane composition between tissues, however,
there was a tendency for red muscle to exhibit higher proportions of PUFAs as well as a decreased PC:PE ratio,
both of which would indicate increased membrane ﬂuidity. In fact, there were signiﬁcant correlations
between IC50 of CPT I for malonyl-CoA and indicators of membrane ﬂuidity across tissues. This supports the
notion that sensitivity of CPT I to its allosteric regulator could be modulated by changes in mitochondrial
membrane composition and/or ﬂuidity.






The regulation of lipid metabolism is complex, and is currently an
extensive area of research. Although there is keen interest into
pathology aspects of lipid metabolism, there are still many unan-
swered questions regarding the normal regulation of cellular lipid
oxidation. In general terms, it has been recognized that mitochondrial
fatty acid oxidation is regulated by both genetic and various other non-
genetic cellular mechanisms that can affect fat entry into, and
oxidation by mitochondria (for review see [1]). For instance, a key
enzyme in mitochondrial β-oxidation, carnitine palmitoyltransferase
(CPT) I, is transcriptionally regulated inmammals, but this enzyme also
experiences allostericmodulation [2], is sensitive to changes in cellular
pH [3], and possibly undergoes covalent modulation [4]. Currently it is
unclearhow these regulatorymechanisms affect CPT I differently and if
regulation is similar across tissues with varying rates of fatty acid
oxidation or even if these mechanisms are evolutionarily conserved.
CPT I is located on the inner side of the outer mitochondrial
membrane and catalyses the conversion of acyl-CoA to fatty acyl-; fax: +1 905 522 6066.
nd).
ll rights reserved.carnitine [5]. Fatty acyl-carnitine can then be transferred into the
mitochondrial matrix by carnitine–acyl-carnitine translocase (CAT)
and converted back to fatty acyl-CoA by the enzyme CPT II. Only acyl-
carnitines can be transferred across the inner mitochondrial mem-
brane, thus, CPT I is thought to be a major regulating step in
mitochondrial fat oxidation [5]. CPT I is allosterically modulated by
malonyl-CoA (M-CoA), which is produced during the ﬁrst step of de
novo fatty acid synthesis by acetyl-CoA carboxylase [6]. This is a simple
mechanism that prevents the oxidation of newly synthesized fats in
the liver [6]. In the muscle, however, where fatty acid synthesis rates
are low,M-CoA is thought to be present solely as a regulator of CPT I [7].
Due to regulatory role of CPT I, changes in its abundance, activity,
or substrate kinetics, as well as the concentration of M-CoA can lead to
changes in overall rates of fatty acid oxidation. In humans and other
mammals, there are two isoforms of the CPT I enzyme, encoded for by
two different genes; L-CPT I (or CPT Iα) which is dominant in the liver,
andM-CPT I (or CPT I-β) which is dominant in skeletal muscle (a brain
isoform has also been identiﬁed) [8]. Both α and β isoforms are
expressed in the heart but at different stages of development in
mammals [9]. McGarry and Brown have shown that in rats, these two
isoforms vary greatly in their kinetics. They have also shown that the
two isoforms differ signiﬁcantly in their sensitivity to M-CoA with M-
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isoform [7].
CPT I has not been studied as extensively in non-mammalian
vertebrates. For example, there is limited information on CPT I activity
or gene expression in different tissues from ﬁsh. In rainbow trout CPT I
has been found to be expressed in various tissues including liver and
muscle, however, it has been suggested that this species expresses
only one CPT I gene which corresponds to the mammalian liver-type
CPT I [10]. To our knowledge, there has neither been a systematic
determination of the sensitivity of CPT I for M-CoA across tissues in
rainbow trout (Oncorhynchus mykiss), nor has the relative expression
levels of CPT I been determined between various tissues. The mRNA
expression of CPT I is thought to be inﬂuenced by the transcription
factor peroxisome proliferator-activated receptor (PPAR), as it con-
tains a PPAR response element (PPRE) [11] at least inmammals. Hence,
it will be important to determine the relative expression of PPARs
across tissues.
Aside from allosteric modulation and changes in gene expression,
mitochondrial membrane composition and ﬂuidity have been pro-
posed to play a role in CPT I regulation [12]. Since CPT I is located in the
outer mitochondrial membrane changes in the properties of the
surrounding membrane can affect enzyme activity and kinetics.
Maintaining a particular state of ﬂuidity in membranes is necessary
for several important cellular functions including ion transport and
protein function, and is the basis for homeoviscous adaptation [13].
Under changing environmental conditions, such as a decrease in
temperature, ectothermic animals selectively incorporate long chain
polyunsaturated fatty acids into their membranes to combat the
effects of temperature on changes in membrane order. As well, other
modiﬁcations such as the ratio between phospholipid classes
phosphatidylcholine (PC) and phophatidylethanolamine (PE) can
also affect ﬂuidity of the membrane due to their differential effects
on membrane order [14].
In vitro studies using rat liver mitochondria have demonstrated
that changing the ﬂuidity of the mitochondrial membrane does affect
the activity of CPT I as well as its sensitivity to M-CoA [12]. This has
also been conﬁrmed through in vivo studies using 48-h fasted rats and
streptozotocin-induced diabetic rats, both of which show decreases in
M-CoA sensitivity paralleled by increases in membrane ﬂuidity as
measured by DPH ﬂuorescence anisotropy [15].
Little is known about these mechanisms in non-mammalian
vertebrates. Fish, in particular naturally experience temperature and
diet induced changes in membrane composition and ﬂuidity [13]. As
well, ﬁsh offer many advantages for the study of muscle ﬁbre-speciﬁc
and tissue-speciﬁc regulation of lipid metabolism since they have
anatomically separated ‘red’ and ‘white’ muscle masses. Previously,
clear ﬁbre type differences have been shown in muscle mitochondrial
proﬁles of rainbow trout, including membrane ﬂuidity [16] but the
effect on CPTI kinetics have not been determined.
The purpose of this study was to evaluate cross-tissue variation in
the capacity for fatty acid oxidation and to identify potential genetic
and non-genetic factors by which it is regulated in rainbow trout
(Oncorhynchus mykiss). More speciﬁcally, we sought to determine; 1)
the non-genetic regulation of CPT I across tissues by examining
differences in Vmax, M-CoA sensitivity, M-CoA concentrations, and
mitochondrial membrane composition, and 2) differences in consti-
tutive transcription for CPT I and transcription factors important for
the expression of genes for fat oxidizing enzymes.
2. Materials and methods
2.1. Experimental ﬁsh
Rainbow trout, Oncorhynchus mykiss, (~500 g) were obtained from a local hatchery
(Humber Springs, Orangeville, ON) and kept in 500 l tanks with circulating water at
12 °C on a commercial ﬁsh diet, Proﬁshent Classic Floating Trout Grower (Martin Mills,
Elmira, ON).2.2. Mitochondrial isolation
Fish were killed by a blow to the head followed by severing of the spinal cord.
Mitochondria were isolated from red muscle (RM), white muscle (WM), heart (H) and
liver (L) from rainbow trout according to Suarez and Hochachka [17] and Moyes et al.
[18]. Each tissue was immediately excised (WM~15 g, RM~4 g, whole H and whole L)
and placed in mitochondrial isolation buffer (MIB) consisting of (in mM) 140 KCl, 10
EDTA, 5 MgCl2, 20 N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES) and
0.5% BSA (pH 7.0) for RM, WM and H, and 250 sucrose, 1 EDTA, 20 HEPES and 0.5% BSA
(pH 7.4) for L, on ice. Tissues were diced, washed twice with fresh chilled MIB, and then
homogenized 3 times, ﬁrst using a wide clearance Teﬂon pestle on a chilled glass
homogenizer, then 3 times with a narrow clearance Teﬂon homogenizer to lyse cells.
Homogenates were centrifuged at 800 ×g for 10 min at 4 °C. For RM, H and L the
supernatant was spun at 9000 ×g for 10 min at 4 °C. WM supernatant was ﬁrst strained
through 2 layers of cheesecloth and then spun at 800 ×g for 10 min at 4 °C, strained
again through 4 layers of cheesecloth and spun again at 9000 ×g for 10 min at 4 °C.
Supernatants for all tissues were then discarded and pellets were resuspended in a
small volume of the appropriate MIB lacking BSA. The resuspended homogenate was
colleted into a 15 ml centrifuge tube and spun again at 9000 ×g for 10 min at 4 °C. The
supernatant was discarded and the mitochondrial pellet was resuspended in an
appropriate volume of MIB lacking BSA and kept on ice.
2.3. Enzyme and protein assays
All assays (except CPT I radioisotope assay) were performed in triplicate at room
temperature using a Spectramax Plus 384 and clear 96-well ﬂat bottom assay plates and
data was analysed using Softmax Pro 4.7.1 software (Molecular Devices, Sunnyvale, CA).
2.3.1. CPTI assay (isotope)
Radioactive CPT I assays followed McGarry et al. [19] for mammals and modiﬁed to
use the assay conditions of Rodnick and Sidell [20] to obtain CPT I Vmax and IC50. The
assay buffer (pH 7.0) contained (in mM) 20 HEPES, 40 KCl, 1 EGTA, 220 sucrose, 0.1 DTT,
0.04 palmitoyl-CoA, 1 carnitine and 1.3 mg/ml BSA. 1 μCi/sample of L-[methyl-3H]
carnitine hydrochloride (speciﬁc activity 82.0 Ci/mmol) (Amersham Biosciences,
Quebec) was added and 70 μl of the assay mixture was placed in 1.5 ml Eppendorf
tubes and incubated with 10 μl of 0.5–500 mM malonyl-CoA or water in place of
mitochondria for blanks or in place of malonyl-CoA andmaximum activity. Tubes sat for
5 min at room temperature. The reaction was started by the addition of 20 μl of
mitochondria diluted 5× in MIB (~2 mg/ml), and incubated at room temperature for
8 min. The reactionwas stopped by the addition of 60 μl of 1 M HCl. The palmitoyl-[3H]-
carnitine was collected according to Starritt et al. [21]. 20 μl of the assay mixture with L-
[methyl-3H]carnitine hydrochloride was also counted in duplicate for determination of
individual speciﬁc activity. Background counts were determined from a blank sample
containing aqueous counting scintillation. The decays per minute (DPM) were read for
5min per sample on a Tricarb 2900 TR Liquid Scintillation Analyzer (PerkinElmer) using
QuantaSmart 1.31 (Packard Instrument Company) analysis software.
2.3.2. CPTI assay (spec)
MIB was used as the assay buffer and contained 0.1 mM 5,5′ Dithiobis (2-nitro-
benzoic acid) (DTNB), 0.1 mM palmitoyl-CoA and 5.0 mM L-carnitine (omitted from
control)±50 µM malonyl-CoA (pH 7.0 for RM, WM, and H; pH 7.4 for L) to determine
Vmax. The reaction was started with 10 µl of mitochondria (~10 mg/ml). Solutions were
mixed and DTNB absorbance read at 412 nm for 5 min. The IC50 was also determined
using this method; however, the sensitivity was lower than the isotope method and
thus yielded much higher IC50 values for all tissues (data not shown).
Frozen tissue samples were powdered using a mortar and pestle chilled with liquid
N2 to determine whole tissue maximum enzyme activity under saturating conditions.
Powdered tissue (50–100mg) was homogenized in 20 volumes of an enzyme extraction
buffer (20 mM HEPES, 1 mM EDTA and 0.1% Triton at pH 7.4) using a glass on glass
homogenizer and enzyme assays were performed on this crude homogenate.
2.3.3. Long-chain acyl-CoA dehydrogenase (LCAD)
LCAD was assayed according to Davidson and Schulz [22]. The assay contained (in
mM) 100 potassium phosphate buffer (pH 7.6) with 0.028 2,6-dichlorophenolindophe-
nol (DCPIP), 0.65 phenazine methosulfate (PMS), 0.2 N-ethylmaleimide and 0.45 KCN.
The reaction was started with the addition of 0.1 mM palmitoyl-CoA and DCPIP
absorbance was monitored at 600 nm. Control wells lacking palmitoyl-CoA were
assayed to correct for background hydrolase activity.
2.3.4. β-hydroxy-acyl-CoA dehydrogenase (HOAD)
The assay followed McClelland et al. [23] and contained (in mM) 50 imidazole (pH
7.4), 0.1 acetoacetyl-CoA, 0.15 NADH and 0.1% Triton 100-X and NADH absorbance was
monitored at 340 nm. Controls lacking substrate were used to correct for background
activity.
2.3.5. CPT II
The assay followed McClelland et al. [23] and contained (in mM) 20 Tris buffer (pH
8.0), 0.1 DTNB and 5 L-carnitine. The reaction was started with the addition of 0.1 mM
palmitoyl-CoA and DTNB absorbance was monitored at 412 nm. Control wells lacking
carnitine were assayed to correct for thiolase activity.
Table 1
Forward (F) and reverse (R) primers used for real-time PCR analysis of mRNA expression
in trout
Gene Primer
EF1α F — 5′ CAT TGA CAA GAG AAC CAT TGA 3′
R — 5′ CCT TCA GCT TGT CCA GCA C 3′
CPT I F — 5′ GCC GCA AAC TAG AGA GAG GA 3′
R — 5′ CCC GTA GTA CAG CCA CAC CT 3′
PPARα F — 5′ CCA AGT TCA GTT TGC CAT GA 3′
R — 5′ ATT GGG GAA GAG GAA GGT GT 3′
PPARβ F — 5′ CTG GAG CTG GAT GAC AGT GA 3′
R — 5′ GTC AGC CAT CTT GTT GAG CA 3′
Fig. 1. The apparent Vmax (in mU per mg total protein) for (A) citrate synthase (CS) and
β-hydroxyacyl-CoA dehydrogenase (HOAD), and (B) long chain acyl-CoA dehydrogenase
(LCAD) and carnitine palmitoyltransferase (CPT) II in white muscle, heart, red muscle
and liver. Values are means±SE for 5 animals. Different symbols denote signiﬁcance
between tissues for each enzyme, pb0.05, similar symbols indicate no signiﬁcant
difference between tissues for each enzyme, pN0.05.
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CS assays followed McClelland et al. [23]. Whole tissue homogenates were frozen
and thawed 3× using liquid N2 and kept on ice until further use. As well, an aliquot of the
5× diluted isolated mitochondria used for the CPT I assay was diluted a further 5× using
the enzyme extraction buffer (see above) and frozen and thawed 3 times using liquid N2
and kept on ice. Isolated intact mitochondria in MIB were also assayed for CS. These
three homogenates were used to determine the amount of intact mitochondria versus
ruptured mitochondria in our CPTI preparations and to extrapolate CPT I enzyme
activities to the tissue level. The CS assay buffer consisted of (in mM) 20 TRIS (pH 8.0),
0.1 DTNB and 0.3 acetyl-CoA. The reaction was started by the addition of 0.5
oxaloacetate and absorbance was monitored at 412 nm. Control wells lacking acetyl-
CoA were assayed to correct for hydrolase activity.
2.3.7. Protein content
Protein concentrations were determined by the Bradford method [24] using a
commercial kit (Bio-Rad).
2.3.8. Malonyl-CoA (M-CoA) content
M-CoA concentrations were determined using a modiﬁed method from Richards
et al. [25]. Brieﬂy frozen tissue samples were powdered using a liquid N2 cooled mortar
and pestle, lyophilized for 24 h and kept at −80 °C until analysis. 50 mg of lyophilized
tissue was homogenized at 4 °C for 20 s using a Teﬂon pestle in 200 µl of 0.5 M
perchloric acid with 50 µM DTE and 10 mg/ml propionyl-CoA used as an internal
standard. Homogenized samples were centrifuged at 20,000 ×g for 10 min at 4 °C and
200 µl of the supernatant was transferred and adjusted to pH 3 using 4 M NaOH while
being vortexed. The sample was transferred to an autosampler vial containing 20 µl of
MOPS (pH 6.8) and the ﬁnal pH was determined (always less than 5). Autosampler vials
were placed in a Waters 717 Plus autosampler (Waters, Missisauga, ON) at room
temperature and M-CoA was separated using reverse-phase HPLC based on a method
from Demoz et al. [26]. For RM, WM and L, 200 µl of the sample was injected onto a
Zorbax ODS Rx C-18 column (25 cm×0.46mm) (Agilent Technologies, Mississauga, ON).
The elution gradient was created using a Waters Model 510 pump controller. Mobile
phase A was 100 mM sodium phosphate and 75 mM sodium acetate in deionized water
(pH4.6).Mobilephase Bwas the sameasAexcept that it contained 30%CH3CN. The elution
gradient was as follows: 0 min, 90% A; 17 min, 50% A; and 17.6 min, 90% A. Baseline
conditions were established after 5 min of 90% A. The ﬂow rate was 1.5 ml/min and
absorbance measurements were made at 254 nm on a Lambda Max 481 LC spectro-
photometer (Waters, Mississauga, ON). For heart, the procedure was the same except that
anextra columnwas added to the loop and theﬂowadjusted to 1ml/min to separate peaks
co-elutingwith theM-CoApeak. Peaksweremanually identiﬁedbycomparisons to known
M-CoA standards and quantiﬁed using the internal standard (propionyl-CoA).
2.4. mRNA quantiﬁcation by real-time PCR
Total RNA from each tissue was extracted using TRIzol Reagent (Invitrogen,
Carlsbad, CA) based on the acid guanidinium thiocyanate-phenol-chloroform extraction
method. Total RNA concentrations were quantiﬁed by UV spectrophotometry at 260 nm
and diluted to 0.5 μg/μl. cDNA was synthesized using 1 μg of DNase (Invitrogen,
Carlsbad, CA) treated RNA and SuperScript RNase H− reverse transcriptase (Invitrogen,
Carlsbad, CA). SYBR green (Bio-Rad, Mississauga, ON) with ROX as a reference dye was
used for quantitative real-time PCR in 25 μl reactions using a Stratagene Mx3000P real-
time PCR system. Each reaction contained 12.5 μl SYBR green mix, 1 μl each of forward
and reverse primer (5 μM), 5.5 μl of DNase/RNase-freewater and 5 μl of 5× diluted cDNA.
Primers were designed using a CPT I sequence from rainbow trout liver [10] (see Table 1
for speciﬁc primer sequences). The thermal program included 3 min at 95, 40 cycles of
95 for 15 s, 60 for 30 s and 72 for 30 s. A no-template control and dissociation curve was
performed to ensure only one PCR product and stock solutions were not contaminated.
Standard curves were constructed for each gene using serial dilutions of stock cDNA to
account for any differences in ampliﬁcation efﬁciencies. All samples were normalized to
the housekeeping gene, EF1-α, which did not change between tissues. Primers were
designed using Primer3 software [27].
2.5. Analysis of mitochondrial membrane phospholipid composition
Mitochondrial total lipid was extracted and phospholipids were analysed according
to Gillis and Ballantyne [28], based on a modiﬁed protocol from Bligh and Dyer [29].Mitochondrial lipid extracts were dried and resuspended in 25 μl chloroform:methanol
(2:1) and spotted along with a standard phospholipid mix (sphingomyelin (SPH),
phosphatidylcholine (PC), phosphatidylserine (PS), phosphatidylinositol (PI), phospha-
tidylethanolamine (PE) and cardiolipin (CL)) (Sigma, Oakville, ON) onto silica gel 60 pre-
coated 250 µM thick plates (Fisher Scientiﬁc, Ottawa, ON) for thin layer chromato-
graphy. The solvent system used to separate the phospholipids was chloroform:
methanol:acetic acid:water (50:37.5:3.5:2, by volume). Once the solvent had run to
within 5 cm of the top of the plate, they were removed, air dried, then sprayed with a
saturated solution of 2,7-dichloroﬂuorescein and allowed to sit in a tank containing 25%
ammonium hydroxide for 5 min. Plates were viewed under UV light and individual
phospholipid fractions (SPH, PC, PS, PI, PE, CL) were scraped into individual Kimex tubes
for saponiﬁcation and methylation. Two ml of 6% sulphuric acid in methanol and 10 μl
heptadecanoic acid as an internal standard (0.6 mg/ml, C17:0) were added to each
fraction and incubated for 2 h at 80 °C. The samples were allowed to cool for 10 min and
1 ml of water and 2 ml of petroleum ether were added and the tubes vortexed. Samples
were spun at 2000 rpm for 6 min and the top phase containing the fatty acid methyl
ester (FAME) fraction was removed into a new tube and dried under N2. The FAMEs
were resuspended in petroleum ether and transferred into autosampler vials for gas
chromatograph analysis. 1 μl of each sample was injected using a 7683B series
automatic injection system (Agilent Technologies) onto a Hewlett–Packard 6890N
series gas chromatograph (GLC) (Agilent Technologies) equipped with either an
Innowax or a DB-23 (J&W Scientiﬁc) 30-m fused silica capillary column (Supelco,
Bellefonte, PA) at 250 °C and followed the following temperature proﬁle: initial oven
temperature was kept at 160 °C for 4 min, ramped up to 220 °C at 2 °C/min, held at
220 °C for 16 min, ramped up to 240 °C at 10 °C/min and held for 2 min. Post-run was
130 °C for 6 min. The ﬂow was 1.8 ml/min and the velocity through the column was
37 cm/s. GLC retention times were veriﬁed using two standards, PUFA No. 3 from
menhaden oil and fatty acid methyl esters mix C4–C24 (Supelco, Bellefonte, PA).
Identiﬁed fatty acids in each phospholipid class were compared to the known internal
standard concentration and then summed for each sample. The percent contribution of
each fatty acid was determined by adding the concentration of that fatty acid from each
phospholipid class and then dividing by the total concentration of all fatty acids in all
phospholipid classes for that sample. The percent contribution of each phospholipid
Fig. 2. CPT activity (mU per mg mitochondrial protein) in liver (L), red muscle (RM),
heart (H) and white muscle (WM). Coloured bars, 0 µM M-CoA; black bars, 50 µM
M-CoA. Values are means±SE for 4 animals. Different letters denote signiﬁcance,
pb0.05.
Table 2
The concentration of malonyl-CoA (µM) to reduce the activity of malonyl-CoA-sensitive
carnitine palmitoyltransferase (CPT) I activity by 50% (IC50) as determined by isotope
assay
Tissue
Liver Red muscle Heart White muscle
IC50 0.079±0.037† 0.55±0.06⁎ 0.40±0.10⁎ 0.37±0.09⁎†
Values are means±SE. Liver and white muscle, n=5; heart, n=4; red muscle, n=3.
Results that share a symbol are not signiﬁcantly different.
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phospholipid class and dividing by the total concentration of all fatty acids in all
phospholipid classes for that sample.
2.6. Statistical analysis
All statistical analyses were performed using SigmaStat (Systat Software Inc., San
Jose, CA). One-way ANOVA and Tukey's tests were used to test for signiﬁcance between
tissues. Correlational analyses were performed using a linear regression. Signiﬁcance
level was set at pb0.05.
3. Results
3.1. Cross-tissue variation in enzymatic activities
The apparent Vmax of citrate synthase (CS), long chain acyl-CoA
dehydrogenase (LCAD), carnitine palmitoyltransferase (CPT) II and
β-hydroxy acyl-CoA dehydrogenase (HOAD) from whole tissue homo-
genates were assayed as indicators of mitochondrial content and fatty
acid oxidationpotential. All fourenzymesdemonstrate the samepattern
of activity across tissues; red muscle having the highest activity,Fig. 3. Inhibition curves determined using a radioisotope assay for carnitine palmitoyltransfe
(M-CoA) concentration in (A) red muscle, (B) heart, (C) white muscle and (D) liver. M-CoA co
red muscle, n=3.followed by heart, then liver, and then white muscle (Fig. 1A–B). Red
muscle CS was signiﬁcantly higher than all other tissues (pb0.001), as
well, heart CS was signiﬁcantly higher than liver and white muscle
(pb0.001). Red muscle and heart LCAD and HOAD were both sig-
niﬁcantly higher than liver and white muscle (pb0.001) but not signi-
ﬁcantly different fromeachother. Redmuscle (pb0.001) andheart CPT II
were signiﬁcantly higher than liver (p=0.013) and white muscle (pb
0.001). There were no signiﬁcant differences between liver and white
muscle for all of the enzymes measured.
Total CPT activity was assayed in isolated mitochondrial prepara-
tions by spectrophotometry. Redmuscle CPT had the highest activity at
26.3±4.0 nmol min−1 mg mito protein−1, which was signiﬁcantly
higher than liver (7.8±0.7 nmol∙min−1 mg mito protein−1) (pb0.001)
and white muscle (14.9±2.7 nmol min−1 mg mito protein−1, p=0.028),
but not signiﬁcantly different from heart CPT activity (16.7±1.4 nmol
min−1 mg mito protein−1, Fig. 2). In the presence of high levels of an
inhibitor (50 μM M-CoA), CPT activity declined in all tissues. In liver,
CPTwas inhibited by 32%whereas in red,white, and heartmuscles CPT
was inhibited by 51%, 70% and 65%, respectively (Fig. 2). This M-CoA
inhibitable activity can be considered as the maximal activity of CPTI.
3.2. Malonyl-CoA inhibition of CPT I
The concentration of malonyl-CoA required to inhibit 50% of the
malonyl-CoA sensitive activity (IC50) of CPT I was determined for each
tissue using a range of M-CoA concentrations from 0.05 μM–50 μM.
Inhibition curves are shown in Fig. 3 (A–D) and the average IC50 for each
tissue inTable2. Liverhadan IC50of 0.079±0.037 μMwhich is signiﬁcantlyrase (CPT)I activity in isolated mitochondrial preparation with increasing malonyl-CoA
ncentrations ranged from 0.05 µM to 50 µM. Liver and white muscle, n=5; heart, n=4;
Table 3
Malonyl-CoA (M-CoA) content across tissues
Tissue
Liver Red muscle Heart White muscle
[M-CoA] (nmol g−1 wet tissue) 0.014±0.004 0.030±0.004 0.013±0.002 0.196±0.027⁎
[M-CoA] (nmol g−1 wet tissue)/U citrate synthase activity 0.0005±1.8×10−4† 0.0001±2.5×10−5 0.00008±1.5×10−5 0.006±8.8×10−4⁎
Values are means±S.E. for 4 animals.
Results that share a symbol are not signiﬁcantly different.
Table 4
Total average mol% contributions of individual fatty acids (FA) to total FA from the
mitochondrial membrane phospholipids across tissues⁎
Fatty acid Liver Red muscle Heart White muscle
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and p=0.05, respectively), but not white muscle (0.37±0.09 μM, pN0.05).
3.3. Malonyl-CoA content
Tissue M-CoA content varied between tissues with WM having
signiﬁcantly higher amounts than all other tissues (pb0.001) (Table 3).
There were no signiﬁcant differences between RM, H, and L. Using
citrate synthase as a marker of mitochondrial density of the tissues,
we show the relationship between M-CoA content and mitochondrial
content for each tissue (Table 3). WM (pb0.001) and L (p=0.49) had
signiﬁcantly higher M-CoA per mitochondria than RM and H which
were not signiﬁcantly different from each other.
3.4. Gene expression proﬁles
The constitutive mRNA expression of CPT I was very low in liver
compared to other muscle tissues (Fig. 4). Liver expression of CPT I is
signiﬁcantly lower than heart expression (p=0.007), however, not
signiﬁcantly different from red and white muscles (pN0.05). PPARα, a
major transcription factor involved in expression of CPT I in mammals,
followed an unexpected pattern. Although CPT I expression was
lowest in the liver, the expression of PPARα tended to be higher than
all other tissues, however only signiﬁcantly different from white
muscle (Fig. 4). In contrast, no signiﬁcant differences were seen
between tissues in the relative expression of PPARβ mRNA.
3.5. Mitochondrial membrane composition proﬁles
Membranes were dominated mainly by the saturated fatty acid
C16:0, comprising 34%, 31%, 33%, and 32% in liver, red muscle, heart
and white muscle, respectively and polyunsaturated fatty acid (PUFA)
C22:6n3, comprising 6%, 28%, 15%, and 10% respectively. There areFig. 4. Real-time PCR gene expression proﬁles in liver, red muscle, heart and white
muscle for carnitine palmitoyltransferase (CPT) I, peroxisome proliferator-activated
receptor (PPAR)α and PPARβ. Values are expressed relative to EF1α. Values are means±
SE. n=4 for each tissue. Different letters denote signiﬁcance within group, pb0.05.quite large differences between tissues in the concentration of
C22:6n3, where liver has a very low amount while red muscle is
quite high, however due to high variability this was not a statistically
signiﬁcant difference (Table 4). Other fatty acids that made a
substantial contribution to the membrane composition include
C18:0, C18:1 and C20:5n3.
The percentage of each phospholipid class in each tissue is
presented in Table 5. As expected, levels of PC and PE were dominant
in all tissues with CL also contributing a large percentage of overall
phospholipid content. There are no major changes in the average
percentages of the various types of fatty acids or in the unsaturation
index (UI) in the different phospholipid classes between tissues.
However, there are considerable differences, although not signiﬁcant,
in the relative proportions of each phospholipid class between tissues
(Table 5). Most notably, the concentrations of PC and PE vary between
tissues. The liver has a higher proportion of PC (53%) compared to red
muscle (44%), heart (49%) and white muscle (42%). PE also varies
between tissues, with the highest proportion being in red muscle
(36%). The ratio of PC:PE is relatively low in redmuscle (1.23±0.09) but
not signiﬁcantly different from other tissues (liver 2.07±0.32, heart
2.06±0.32, white muscle 2.02±0.31). While there are no signiﬁcant
differences between the average values of the classes of phospholipids
between tissues, when presented in relation to CPT I inhibition, there
are signiﬁcant correlations (see below). Sphingomyelin was found in
trace amounts indicating low contaminationwith other cellular mem-
branes (data not shown).C14:0 2.5±0.5 3.8±1.3 4.3±1.7 5.1±1.4
C16:0 34.2±2.0 30.6±3.0 32.9±4.4 32.1 ± 0.7
C16:1 5.5±1.2 6.2±2.5 7.6±3.2 9.6±2.6
C18:0 8.0±2.3 7.8±1.3 8.5±0.9 7.4±0.3
C18:1n9 5.1±3.0 3.5±1.3 10.7±2.1 6.6±2.0
C18:1n7 10.8±2.1 8.0±3.7 6.5±2.6 7.1±1.6
C18:2n6 8.5±0.8 6.3±0.8 5.0±1.2 5.4±1.2
C18:3n3 0.6±0.1 0.6±0.1 n.d. 0.7±0.1
C18:4n3 0.6±0.3 n.d. 1.1±0.6 n.d.
C20:1n9 3.5±0.7 3.8±0.9 2.3±0.8 1.7±0.3
C20:4n6 2.7±0.5 1.5±0.2 2.4±0.5 1.2±0.2
C20:5n3 10.9±3.6 2.7±1.9 1.6±1.0 7.3±2.6
C22:5n3 1.9±1.4 3.4±0.8 4.8±2.0 7.5±4.0
C22:6n3 5.8±4.8 21.5±12.3 11.6±6.2 10.4±8.3
Saturates 44.9±3.6 42.2±4.4 45.8±3.8 44.6±0.7
Monounsaturates 25.1±1.9 21.5±7.3 27.1±5.3 25.1±3.7
Polyunsaturates 29.9±1.8 36.3±11.0 27.0±3.1 30.3±4.4
η-3 polyunsaturates 18.6±1.4 28.4±10.8 19.6±3.8 23.6±4.4
η-6 polyunsaturates 11.3±0.8 7.8±0.7 7.5±1.3 6.6±1.0
η-3/η-6 1.7±0.1 3.6±1.3 3.1±0.9 3.9±1.2
UI† 148.9±9.6 202.6±59.8 154.4±20.3 164.9±22.8
Values are means±S.E., n=4.
⁎Values are means±SE; n.d. = not detectable.
†Unsaturation index=Σmi d ni; wheremi is the mole percentage and ni is the number of
C–C double bonds in the fatty acid “i”.
Fig. 5. The relationship between mitochondrial membrane composition and sensitivity
of carnitine palmitoyltransferase (CPT) I to malonyl-CoA (IC50) across tissues.
(A) Negative correlation between the PC:PE ratio and IC50. Liver, n=4; red muscle, n=3;
heart, n=3; white muscle, n=4. (B) Positive correlation between the % of docosahexanoic
acid (DHA) and IC50. Liver, n=3; red muscle, n=3; heart, n=2; white muscle, n=3.
Table 5
Mol% of mitochondrial membrane phospholipid classes across tissues⁎
Phospholipid Liver Red muscle Heart White muscle
Phosphatidylcholine 52.7±2.5 43.7±3.5 49.0±7.7 41.9±2.1
Phosphatidylserine 2.5±0.6 4.6±1.7 6.5±2.8 6.2±2.3
Phosphatidylinositol 8.0±3.0 5.7±2.7 7.7±2.9 13.3±4.4
Phosphatidylethanolamine 27.2±4.3 35.7±2.5 23.9±1.2 22.4±4.3
Cardiolipin 9.5±1.1 13.9±2.8 13.0±2.2 16.0±2.0
PC:PE† 2.1±0.3 1.2±0.1 2.1±0.3 2.0±0.3
Values are means±S.E., n=4.
⁎Values are means±SE.
†PC = phosphatidylcholine, PE = phosphatidylethanolamine.
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Signiﬁcant correlations can be drawn from the current CPT I in-
hibition data and the mitochondrial membrane composition. There is a
negative correlation between IC50 based on isotope determination and
PC:PE ratio, indicating that as the PC:PE ratio increases, IC50 decreases,
thus, increasing the sensitivity to M-CoA (p=0.002) (Fig. 5). Moreover, a
correlation exists between IC50 and the percent of docosahexanoic acid
(DHA, C22:6n3) in the membrane (p=0.021, Fig. 5). As the %DHA in-
creases the IC50 increases, thus, decreasing the sensitivity to M-CoA.
4. Discussion
The regulation of CPT I and fat oxidation occurs by both genetic and
non-geneticmechanisms.We found intrinsic differences in sensitivity of
CPT I to the allosteric inhibitorM-CoA. Across tissues differences exist in
1) M-CoA content, 2) membrane composition, and 3) in constitutive
mRNA expression for genes involved in the fat oxidation pathway. In
general the apparent Vmax for enzymes involved in mitochondrial fat
oxidation followed the pattern red muscleNheartN liverNwhite muscle
on a per gram tissuebasis.Maximal activity of CPT Imeasured in isolated
mitochondria followed a similar pattern of red muscleNheartNwhite
muscleN liver suggesting that both mitochondrial quantity and quality
play a role in tissue fat oxidative capacity. This pattern can be partially
explained by tissue differences in mRNA expression pattern of
heartNred muscleNwhite muscleN liver for CPT I. In contrast, the
expression pattern of transcription factors PPARα and β did not
correspond to enzyme patterns across tissues. Tissue malonyl-CoA
content was highest in white muscle than other tissues and there were
no differences between the other tissues. Amongst the factors that
appear to be involved in non-genetic regulation of fat oxidation
mitochondrial membrane ﬂuidity has received little attention. Here
we ﬁnd signiﬁcant correlations between key indices of membrane
ﬂuidity (%DHA and PC:PE) and sensitivity (IC50) of CPT I to its allosteric
regulator M-CoA.
4.1. Enzyme activity
Patterns of enzyme Vmax across tissues are useful in revealing
differences in fatty acid oxidation capacity and also stoichiometry of
various enzymes in this pathway. Redmuscle and heart have distinctly
higher activities for CS, LCAD, CPT II and HOAD on a per gram protein
basis when compared to white muscle and liver. CS is commonly used
as marker of mitochondrial density [30], thus, it is clear that red
muscle and heart have higher mitochondrial densities which leads to
increased activities of mitochondrial fatty acid oxidation enzymes and
the potential for higher rates of fat oxidation. Further to this, the
activity of CPT I, thought to be the regulating enzyme of fat entry into
the mitochondria, also exhibits tissue differences (but on a per mg
mitochondrial protein basis). This suggests that mitochondria are not
equivalent and that there are tissue-speciﬁc qualitative differences in
fat oxidative ability per unit mitochondria. Similar patterns have been
observed by others for CPT I activity per g tissue in rainbow trout, withred muscle and heart having the highest activity followed by liver and
thenwhite muscle [10,31]. However, our data suggests that liver CPT I
has signiﬁcantly lower activity compared to red muscle and that heart
and white muscle have an intermediate activity level (Fig. 2). This data
shows that there are stoichiometric changes in enzyme content with
differences in fatty acid oxidation capacity across tissues and that this
occurs through quantitative differences in mitochondrial density and
qualitative differences in β-oxidation ability of each mitochondrial
unit.
4.2. Allosteric regulation of CPT I
M-CoA reduced CPT I activity by allosteric inhibition in all tissues,
however, to varying extents (Figs. 2 and 3A–D). At high levels of M-
CoA liver, red, white and heart muscles were inhibited by 32%, 51%,
70% and 65%, respectively. Residual activity in each tissue may be due
to activity of CPT II which is M-CoA insensitive and can be expressed if
membranes are damaged during mitochondrial preparation. The
mitochondrial preparations used in these experiments were between
60–85% intact depending on the tissue (based on CS measurements).
However this cannot explain all of theM-CoA insensitive activity since
liver mitochondrial preparations were 85% intact but had the highest
residual activity (Fig. 3). Alternatively, it may be due to a M-CoA
insensitive splice variants of CPT I as seen in rat red muscle [32]. We
determined the IC50 for M-CoA sensitive moiety of CPT I in all tissues
and have found that the liver (IC50=0.079 µM) is signiﬁcantly more
sensitive to M-CoA than red muscle (IC50=0.55 µM). In contrast, in
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in liver [7]. In ﬁsh, it appears that the opposite is true, liver CPT I is
approximately 10 times more sensitive than muscle CPT I to M-CoA.
However, this is a small difference compared to that seen between
tissues in mammals.
The M-CoA content varied across tissues but was only signiﬁcantly
different in white muscle compared to the other 3 tissues. White
muscle M-CoA content (0.19 nmolg−1 wet weight) is similar to the
only other data published on any tissue rainbow trout [25]. When the
M-CoA content is expressed per unit citrate synthase, a mitochondrial
density marker, it suggests that white muscle and liver have
signiﬁcantly higher M-CoA concentrations per unit mitochondria.
Although these tissues also had the lowest CPT I activities per mg
mitochondria this relatively high inhibitor concentration most likely
contributes to low in vivo fat oxidation capacities.
Interestingly, our data indicate no changes in M-CoA between red
muscle, heart and liver, which can be interpreted in a number of ways.
It would be expected that liver would have higherM-CoA content than
other tissues because it is the primary site of fat synthesis. On the
other hand, we have shown here that liver CPT I is signiﬁcantly more
sensitive to M-CoA than other tissues. It is possible that in trout
hepatocyte M-CoA concentrations are kept low to prevent total
inhibition of CPT I and maintain fatty acid oxidation. In fact resting
levels of M-CoA in all tissues were well below the IC50 (Table 2, 3).
4.3. Gene expression proﬁle
CPT I has been found to be expressed in many tissues of rainbow
trout [10]. However, the relative expression levels across tissueshavenot
been previously determined in this species. Using real-time PCR we
show that CPT I expressionwas very low in the liver compared to heart,
but not signiﬁcantly different from red and white muscles (Fig. 4). The
low expression of CPT I in liver corresponds to its low activity (Fig. 2).
Unlike mammals which express two different CPT I isoforms, trout are
thought to express a single isoformandphylogenetic analysis has shown
it to be similar to mammalian CPT I-α [10]. However, it is possible that
our measurements reﬂect the expression of an uncharacterized muscle
isoform which is expressed at low levels in liver. Moreover, the
differences in CPT I kinetics between tissues shown here, are very
suggestive of second isoform in trout. Thiswould not be surprising since
salmonids have gone through several genome duplications and possibly
have retained 50–75% of the loci as duplicates [33]. However, intertissue
differences in enzymemilieu could be a nongenomic explanation for the
intertissue kinetic differences (see below).
In mammals many fatty acid oxidation genes have been shown to
have PPAR response elements (PPRE) to which PPARs can bind and
induce gene expression, including CPT I, CPT II and LCAD [11].
Surprisingly, the expression of PPARα across tissues was quite
different from that of CPTI, with the highest, not lowest, expression
in liver. The present data may be explained if in ﬁsh: 1) the PPARα
gene expression is not translated to protein, 2) CPT I does not contain a
PPRE, 3) this isoform performs a different role than in mammals, 4)
there are more than one PPARα isoform as is the case for PPARβ in
zebra ﬁsh [34], or 5) CPT I gene expression is regulated independently
of PPARα as seen in rat hepatoma cells [35]. It is also possible that
basal and inducible CPT expression occur by different pathways. Basal
transcription of CPTI in ﬁsh might be regulated by the transcription
factor SP1 as has been suggested for mammals [36], while inducible
expression is controlled by the PPARs.
There were no differences in the expression of PPARβ between any
of the tissues (Fig. 4). Very little is known about the roles of PPARβ,
however, it has recently been shown to play a variety of roles
depending on developmental stage, gender and diet [37,38]. In adult
animals, PPARβ is expressed rather ubiquitously [39]. Our results
show a ubiquitous and uniform expression across tissues in adult
rainbow trout. These results are similar to those found in brown trout[40] and rats [41] and may suggest that in adult trout, PPARβ plays a
role in homeostatic lipid metabolism but not in determining tissue
differences in fat oxidation machinery.
4.4. Mitochondrial membrane composition and relation to CPT I IC50
Both the fatty acid tail composition and the phospholipid head
groups contribute to the overall ﬂuidity, with increases in PUFAs (large
“kinked” fatty acid tails) and PE (a membrane destabilizing phospho-
lipid) contributing to increased ﬂuidity [42,14]. There has been no
systematic investigation of tissue-speciﬁc differences in mitochon-
drial membrane composition of the same animal that may be
contributing to the differences in membrane ﬂuidity or fat oxidation
capacity [16]. Past interest in membrane remodelling has focused on
single tissue changes during temperature acclimation that ensure
proper membrane ﬂuidity to preserve function at low temperature
(for review see [14]). As well, comprehensive studies across reptiles
and mammals have shown that the activity of mitochondrial
membrane bound enzymes is positively correlated to the unsaturation
of the mitochondrial membrane fatty acids [43].
In the present study fatty acids contributing the most to the
composition of the mitochondrial membranes were C16:0, C18:0,
C18:1, C20:5n3 and C22:6n3 (Table 4). This composition is similar to
those observed by Kraffe et al. in their investigation of trout red
muscle mitochondria [44]. Moreover, here the majority of the fatty
acids were found in phospholipid classes PC and PE and to some
extent in CL (Table 5). We found no signiﬁcant differences in the fatty
acid composition between tissues. However, red muscle tended to
have higher concentrations of PUFAs (Table 4) and lower PC:PE ratios
(Table 5), both of whichmay indicate an increase in ﬂuidity. Leary et al.
directly measured mitochondrial membrane ﬂuidity in rainbow trout
muscles and found that red muscle is more ﬂuid when compared to
white muscle and heart [16]. Recently, it has been suggested that
increases in membrane ﬂuidity may disrupt the interaction between
the N- and C-termini of CPT I and be partly responsible for the
decrease in the sensitivity of CPT I toM-CoA [45,46].We investigated if
there were any correlations that might explain the variation in the
data and suggest a role of membrane composition in the regulation of
CPT I. Signiﬁcant correlations exist when the IC50 values are plotted
against important determinants of membrane ﬂuidity, PC:PE ratio and
%DHA (Fig. 5A–B). Lower PC:PE ratio and higher %DHA may lead to
increases in membrane ﬂuidity, with changes in phospholipid head-
groups (PC:PE) probably having a greater affect than changes in DHA
proportions [14]. The differences, particularly in PC:PE across tissues
could potentially decrease the sensitivity of CPT I to M-CoA. It should
be noted that the measurements presented in this study are for both
inner and outer mitochondrial membranes while CPT I only resides in
the outer membrane. Direct ﬂuidity measurements using DPH
anisotropy, as opposed to membrane composition studies will be
valuable in assessing actual outer mitochondrial membrane ﬂuidity
and verify our current ﬁndings.
This evidence suggests that in ﬁsh, sensitivity to M-CoA may be
regulated by the ﬂuidity of the membrane as indicated by the
mitochondrial membrane composition, but currently it is unclear if
this occurs by a common mechanism to that proposed for mammals
[46]. Perhaps as part of homeoviscous adaptations, ﬁsh may be able to
maintain suitable rates of mitochondrial fat oxidation at low
environmental temperatures through this interaction between mem-
brane ﬂuidity and CPT I kinetics. This would help compensation for the
decelerating effects of temperature on metabolism.
4.5. Fish vs. mammals
It is interesting to note the dramatic differences between rainbow
trout and rat CPT I kinetics, especially in IC50 values. The liver
mitochondria of rainbow trout tend to oxidize pyruvate at a higher rate
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are preferentially oxidized over pyruvate [47]. While this may explain
the difference in liver CPTI sensitivity to M-CoA, it does not explain the
differences in muscle sensitivity seen between rats and ﬁsh, as lipids
are an important fuel source for endurance exercise in both species
[48]. In rats, the IC50 of CPT I for M-CoA is approximately 0.03 µM [7],
whereas, in trout red muscle it is approximately 18 times higher
(IC50=0.55 µM). Theremay be differences in skeletalmuscleﬁbre types
in rats that are being masked in the mixed muscle samples that are
most conveniently elucidated by separating out the anatomically
distinct ﬁbre types in ﬁsh.
5. Conclusions
Fatty acid oxidation is regulated by both genetic and non-genetic
mechanisms. There is a growing body of evidence from mammals
[12,15,46,49,50] indicating that the ﬂuidity of the mitochondrial
membrane inﬂuences the sensitivity of CPT I to M-CoA. The present
study suggests that this phenomenon extends across taxa. Isolated
mitochondria fromwhite, red and heartmuscles of rainbow trout have
been shown to exhibit dramatic differences in a variety of components
such as proton leak kinetics and ﬂuidity [16]. We have shown tissue-
speciﬁc differences in a variety of factors affecting fatty acid oxidation
in rainbow trout. Most dramatically, red muscle and liver show sig-
niﬁcant differences in CPT I kinetics. These kinetic differences match
changes in gene expression of CPT I and tissue differences in mito-
chondrial membrane composition across tissues. In contrast to a
previous study [10], these differences suggest the possibility of a
second CPT I isoform in ﬁsh. It will now be important to determine if
changing these factors through in vivo perturbations such as diet and
temperature acclimation will affect these tissues in the same or
different manner and if it will have effects on overall mitochondrial
fatty acid oxidation. Studying the tissue-speciﬁc differences in fat
oxidation and gene expression which reﬂect developmental differ-
ences in tissue function also provides a window into species-speciﬁc
differences in abilities to use fat as a metabolic substrate.
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